Anti-SARS-CoV-2 spike glycoprotein antibodies and therapeutic uses thereof

• Main Authors: BARTH JANET L, ABDICHE YEHUDA N, LUDINK, IVAN
• Format: Patent
• Language: Chinese; English
• Published: 23.01.2024
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

The present application relates to neutralizing antibodies, or antigen binding fragments thereof, against beta coronavirus, such as Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2); nucleic acids encoding such neutralizing antibodies or antigen binding fragments thereof; as well as mixtures and compositions comprising such antibodies, antigen binding fragments or nucleic acids. Such neutralizing antibodies or antigen-binding fragments thereof are capable of blocking beta coronavirus entry into cells and/or inducing complement-dependent cytotoxic effects (CDC), antibody-dependent cytotoxic effects (ADCC), and/or antibody-dependent cytophagy effects (ADCP) against cells infected with beta coronavirus. Also described are methods and uses of the antibodies, antigen binding fragments thereof, nucleic acids or compositions, including therapeutic, diagnostic and prophylactic methods and uses for beta coronavirus infections and related diseases, such as COVID-19. 本申请涉及针对β冠状病毒，诸如严重急性呼吸道综合征冠状病毒2(SARS-CoV-2)